Non-Insulin Dependent Diabetes Mellitus (NIDDM) and Angiotensin Converting Enzyme 2 (ACE2): Diabetic Patients Treated With Antihypertensive Drugs
Recruitment status was: Not yet recruiting
This feasibility study is designed to examine modulation of the relative activities of ACE and ACE2 in diabetic patients following treatment with the angiotensin type 1 receptor (AT1R) antagonist, Candesartan.
This study will provide a closer insight to the possible involvement of the renin-angiotensin system (RAS)-related enzymatic components in development or attenuation of vascular pathogenesis.
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Educational/Counseling/Training
|Official Title:||ACE/ACE2 Ratio in Diabetic Patients Treated With Antihypertensive Drugs|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00192803
|Internal Ward "A", Rambam Medical Center|
|Principal Investigator:||Shlomo Keidar, MD||Rambam Health Care Campus|